var data={"title":"Pegaspargase: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pegaspargase: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6730?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pegaspargase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pegaspargase: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pegaspargase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pegaspargase: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206778\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Oncaspar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50616077\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Oncaspar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206800\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Enzyme;</li>\n      <li>\n        Antineoplastic Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206781\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Acute lymphoblastic leukemia (ALL):</b> IM, IV: 2500 units/m<sup>2</sup> (as part of a combination chemotherapy regimen), do not administer more frequently than every 14 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206794\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pegaspargase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pegaspargase: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Acute lymphoblastic leukemia (ALL):</b> IM, IV: Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206782\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7697743\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22125178\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no initial dosage adjustments provided in the manufacturer&rsquo;s labeling. The following adjustments have been recommended (Stock 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALT/AST &gt;3 to 5 times ULN: Continue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALT/AST &gt;5 to 20 times ULN: Delay next dose until transaminases &lt;3 times ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALT/AST &gt;20 times ULN: Discontinue therapy if it takes longer than 1 week for transaminases to return to &lt; 3 times ULN. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Direct bilirubin &lt;3 mg/dL: Continue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Direct bilirubin 3.1 to 5 mg/dL: Hold pegaspargase and resume when direct bilirubin &lt;2 mg/dL; consider switching to alternate asparaginase product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Direct bilirubin &gt;5 mg/dL: Discontinue pegaspargase; do not substitute other asparaginase products; do not make up for missed doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44305358\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">The following adjustments have been recommended (Stock 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hyperammonemia-related fatigue:</i> Continue therapy for grade 2 toxicity. If grade 3 toxicity occurs, reduce dose by 25%; resume full dose when toxicity &le;grade 2 (make up for missed doses). If grade 4 toxicity occurs, reduce dose by 50%; resume full dose when toxicity &le;grade 2 (make up for missed doses).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hyperglycemia:</i> Continue therapy for uncomplicated hyperglycemia. If hyperglycemia requires insulin therapy, hold pegaspargase (and any concomitant corticosteroids) until blood glucose controlled; resume dosing at prior dose level. For life-threatening hyperglycemia or toxicity requiring urgent intervention, hold pegaspargase (and corticosteroids) until blood glucose is controlled with insulin; resume pegaspargase and do not make up for missed doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hypersensitivity reactions:</i> May continue dosing for urticaria without bronchospasm, hypotension, edema, or need for parenteral intervention. If wheezing or other symptomatic bronchospasm with or without urticaria, angioedema, hypotension, and/or life-threatening hypersensitivity reactions occur, discontinue pegaspargase. Replace pegaspargase with asparaginase (Erwinia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hypertriglyceridemia:</i> If serum triglyceride level &lt;1,000 mg/dL, continue pegaspargase but monitor closely for pancreatitis. If triglyceride level &gt;1,000 mg/dL, hold pegaspargase and monitor; resume therapy at prior dose level after triglyceride level returns to baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Pancreatitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asymptomatic amylase or lipase &gt;3 times ULN (chemical pancreatitis) or radiologic abnormalities only: Continue pegaspargase and monitor levels closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clinical pancreatitis (abdominal pain with amylase or lipase &gt;3 times ULN for &gt;3 days and/or development of pancreatic pseudocyst): Permanently discontinue pegaspargase.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Thrombosis and bleeding, CNS:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Thrombosis: Continue therapy for abnormal laboratory findings without a clinical correlate. If grade 3 toxicity occurs, discontinue therapy; if CNS signs/symptoms are fully resolved and further pegaspargase doses are required, may resume therapy at a lower dose and/or longer intervals between doses. Discontinue therapy for grade 4 toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemorrhage: Discontinue therapy; do not withhold therapy for abnormal laboratory findings without a clinical correlate. If grade 3 toxicity occurs, discontinue therapy; if CNS signs/symptoms are fully resolved and further pegaspargase doses are required, may resume therapy at a lower dose and/or longer intervals between doses. Discontinue therapy for grade 4 toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Thrombosis and bleeding, non-CNS:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Thrombosis: Continue therapy for abnormal laboratory findings without a clinical correlate. If grade 3 or 4 toxicity occurs, withhold therapy until acute toxicity and clinical signs resolve and anticoagulant therapy is stable or completed. Do not withhold therapy for abnormal laboratory findings without clinical correlate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemorrhage: If grade 2 bleeding in conjunction with hypofibrinogenemia occurs, withhold therapy until bleeding &le; grade 1. Do not withhold therapy for abnormal laboratory findings without clinical correlate. For grade 3 or 4 bleeding, withhold therapy until bleeding &le; grade 1 and until acute toxicity and clinical signs resolve and coagulant replacement therapy is stable or completed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206757\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oncaspar: 750 units/mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206742\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206760\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Have available appropriate agents for maintenance of an adequate airway and treatment of a hypersensitivity reaction (antihistamine, epinephrine, oxygen, IV corticosteroids). Be prepared to treat anaphylaxis at each administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">IM: Must only be administered as a deep intramuscular injection into a large muscle. Do not exceed 2 mL per injection site; use multiple injection sites for IM injection volume &gt;2 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Administer over 1 to 2 hours through a running IV infusion line; <b>do not administer IV push. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206758\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia and hypersensitivity to asparaginase:</b> Treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to native forms of L-asparaginase (as a component of a multiagent chemotherapy regimen)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Acute lymphoblastic leukemia, first-line:</b> First-line treatment of ALL (as a component of a multiagent chemotherapy regimen)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206808\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oncaspar may be confused with Elspar</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pegaspargase may be confused with asparaginase (<i>E. coli</i>), asparaginase (<i>Erwinia</i>), peginesatide</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206749\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum transaminases (ALT, AST; grades 3/4: 3% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (grades 3/4: 1%, includes anaphylaxis, bronchospasm, erythema, hives, hypotension, laryngeal edema, skin rash, swelling, urticaria; relapsed acute lymphoblastic leukemia [ALL] with no prior asparaginase hypersensitivity: 10%; relapsed ALL with prior asparaginase hypersensitivity: 32%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Thrombosis (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Cerebral thrombosis (or hemorrhage of the brain: 2%; grades 3/4: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hyperglycemia (3% [some patients required insulin therapy]; grades 3/4: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Pancreatitis (1%; grades 3/4: 2% [includes 3 deaths])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic: Blood coagulation disorder (grades 3/4: 2% to 7%; includes prolonged prothrombin time or partial thromboplastin time or decreased serum fibrogen)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Abnormal hepatic function tests (grades 3/4: 5%), hyperbilirubinemia (grades 3/4: 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immunologic: Hypersensitivity to L-asparaginase (grades 3/4: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, case reports, and/or frequency not defined: Abdominal pain, anemia, anorexia, antithrombin III deficiency, arthralgia, ascites, bacteremia,  bronchospasm, bruise, chest pain, chills, coagulation time increased, colitis, confusion, constipation, cough, deep vein thrombosis, disseminated intravascular coagulation, dizziness, dyspnea, edema, emotional lability, endocarditis, epistaxis, facial edema, fatigue, fever, gastrointestinal pain, headache, hematuria, hemolytic anemia, hemorrhagic cystitis, hepatic failure, hepatomegaly, hyperammonemia, hypertension, hyperuricemia, hypoalbuminemia, hypoglycemia, hyponatremia, increased blood urea nitrogen, increased serum amylase, increased serum creatinine, increased serum lipase, increased thirst, injection site pain, jaundice, leukopenia, lip edema, liver steatosis, malaise, metabolic acidosis, myalgia, nausea, night sweats, ostealgia, pancytopenia, paresthesia, petechial rash, prolonged prothrombin time, proteinuria, purpura, renal failure, renal function abnormality, sagittal sinus thrombosis, seizure, sepsis, septic shock, subacute bacterial endocarditis, superficial venous thrombosis, tachycardia, thrombocytopenia, uric acid nephropathy, urticaria, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206763\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">History of serious allergic reactions to pegaspargase or any component of the formulation; history of any of the following with prior L-asparaginase treatment: serious thrombosis, pancreatitis, and/or serious hemorrhagic events</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe hepatic impairment (bilirubin &gt;3 times upper limit of normal [ULN]; transaminases &gt;10 times ULN).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206746\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reactions: Anaphylaxis and serious allergic reactions (eg, bronchospasm, hypotension, laryngeal edema, local erythema or swelling, systemic rash, urticaria) may occur; discontinue in patients with serious allergic reaction. The risk of serious allergic reactions is increased in patients with a history of hypersensitivity reactions to other L-asparaginase products. Observe patients for 1 hour after administration; equipment and immediate treatment for hypersensitivity reactions should be available during administration.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Coagulopathy: Increased prothrombin time, increased partial thromboplastin time, and hypofibrinogenemia may occur. Severe or symptomatic coagulopathy may require treatment with fresh-frozen plasma. Use cautiously in patients with an underlying coagulopathy or previous hematologic complications from asparaginase. Monitor coagulation parameters at baseline and periodically during and after therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose intolerance: May cause glucose intolerance; irreversible in some cases. Use with caution in patients with diabetes mellitus and hyperglycemia. Monitor serum glucose. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Altered liver function tests (eg, increased AST, ALT, alkaline phosphatase, bilirubin [direct and indirect], and decreased serum albumin, plasma fibrinogen) may occur with therapy. Use with caution in patients with pre-existing hepatic impairment. Monitor liver function tests at baseline and periodically during treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: May occur; promptly evaluate patients with abdominal pain. The manufacturer recommends discontinuing pegaspargase  if pancreatitis occurs during treatment. May consider continuing therapy for asymptomatic chemical pancreatitis (amylase or lipase &gt;3 times ULN) or only radiologic abnormalities; monitor closely for rising amylase and/or lipase levels (Stock 2011). Discontinue permanently for clinical pancreatitis (eg, vomiting, severe abdominal pain) with amylase/lipase elevation &gt;3 times ULN for &gt;3 days and/or development of a pancreatic pseudocyst. Avoid alcohol use (Stock 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic events: Serious thrombotic events, including sagittal sinus thrombosis may occur; discontinue with serious thrombotic event. Anticoagulation prophylaxis during therapy may be considered in some patients (Farge 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration route: In a study comparing IV pegaspargase to IM native <i>E. coli</i> asparaginase for post-induction treatment in children with ALL, 5-year disease-free survival did not differ and the overall frequency of asparaginase-related toxicities (including allergy, pancreatitis, and thrombotic or bleeding complications) did not differ between the IV pegaspargase and IM native <i>E. coli</i> apsaraginase groups. The median nadir serum asparaginase activity was significantly higher in the IV pegaspargase group. Reported treatment-related anxiety was significantly lower (for both patients and guardians) in the group that received IV pegaspargase (Place 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Medication error prevention: Do not interchange pegaspargase for asparaginase (<i>E. coli</i>) or asparaginase (<i>Erwinia</i>); ensure the proper asparaginase formulation, route of administration, and dose prior to administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299829\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222178\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9745&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: May diminish the therapeutic effect of Pegaspargase.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206753\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206766\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with pegaspargase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2238576\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pegaspargase is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206755\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, platelets, amylase/lipase, liver function tests (baseline and periodically during treatment), fibrinogen, PT, PTT (coagulation parameters [baseline and periodically during and after treatment]), renal function tests; urine glucose, blood glucose; triglycerides; uric acid; vital signs during administration; monitor for onset of abdominal pain; observe for allergic reaction (for 1 hour after administration); signs/symptoms of thrombosis or bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206745\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pegaspargase is a modified version of L-asparaginase, conjugated with polyethylene glycol. In leukemic cells, asparaginase hydrolyzes L-asparagine to ammonia and L-aspartic acid, leading to depletion of asparagine. Leukemia cells, especially lymphoblasts, require exogenous asparagine; normal cells can synthesize asparagine. Asparagine depletion in leukemic cells leads to inhibition of protein synthesis and apoptosis. Asparaginase is cycle-specific for the G<sub>1</sub> phase of the cell cycle. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206762\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset: Asparagine depletion: IM: Within 4 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Asparagine depletion: IV (in asparaginase naive adults): 2 to 4 weeks (Douer 2007); IM: ~21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Not absorbed from the GI tract; therefore, requires parenteral administration; IM: Slow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Apparent V<sub>d</sub>: Plasma volume: IM: Children: 1.5 L/m<sup>2</sup>; IV: Adults (asparaginase naive): 2.4 L/m<sup>2 </sup> (Douer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Systemically degraded </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Children: 5.8 days; Adults: 5.5-6 days; 3.2 &plusmn; 1.8 days in patients who previously had a hypersensitivity reaction to native L-asparaginase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Adults (asparaginase naive): 7 days (Douer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IM: 3 to 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Clearance is unaffected by age, renal function, or hepatic function; not detected in urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323630\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Oncaspar Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 units/mL (5 mL): $17,453.45</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038720\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ai Yang (CN);</li>\n      <li>Oncaspar (BB, CZ, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abshire TC, Pollock BH, Billett AL, et al, &quot;Weekly Polyethylene Glycol Conjugated L-Asparaginase Compared With Biweekly Dosing Produces Superior Induction Remission Rates in Childhood Relapsed Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study,&quot; <i>Blood</i>, 2000, 96(5):1709-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-drug-information/abstract-text/10961868/pubmed\" target=\"_blank\" id=\"10961868\">10961868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asselin BL, Whitin JC, Cappola DJ, et al, &ldquo;Comparative Pharmacokinetic Studies of Three Asparaginase Preparations,&rdquo; <i>J Clin Oncol</i>, 1993, 11(9):1780-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-drug-information/abstract-text/8355045/pubmed\" target=\"_blank\" id=\"8355045\">8355045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avramis VI, Sencer S, Periclou AP, et al, &ldquo;A Randomized Comparison of Native <i>Escherichia Coli</i> Asparaginase and Polyethylene Glycol Conjugated Asparaginase for Treatment of Children With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study,&rdquo; <i>Blood</i>, 2002, 99(6):1986-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-drug-information/abstract-text/11877270/pubmed\" target=\"_blank\" id=\"11877270\">11877270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avramis VI and Spence SA, &ldquo;Clinical Pharmacology of Asparaginases in the United States: Asparaginase Population Pharmacokinetic and Pharmacodynamic (PK-PD) Models (NONMEM) in Adult and Pediatric Patients,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2007, 29(4):239-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-drug-information/abstract-text/17414566/pubmed\" target=\"_blank\" id=\"17414566\">17414566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douer D, Yampolsky H, Cohen LJ, et al, &ldquo;Pharmacodynamics and Safety of Intravenous Pegaspargase During Remission Induction in Adults Aged 55 Years or Younger With Newly Diagnosed Acute Lymphoblastic Leukemia,&rdquo; <i>Blood</i>, 2007, 109(7):2744-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-drug-information/abstract-text/17132721/pubmed\" target=\"_blank\" id=\"17132721\">17132721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>J Thromb Haemost</i>. 2013;11(1):56-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-drug-information/abstract-text/23217107/pubmed\" target=\"_blank\" id=\"23217107\">23217107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oncaspar (pegaspargase) [prescribing information]. Gaithersburg, MD: Sigma-Tau; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oncaspar (pegaspargase) [product monograph]. Mississauga, Ontario, Canada: Baxalta Canada Corporation; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. <i>Lancet Oncol</i>. 2015;16(16):1677-1690.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-drug-information/abstract-text/26549586/pubmed\" target=\"_blank\" id=\"26549586\">26549586</a>]</span><span class=\"doi\">10.1016/S1470-2045(15)00363-0</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. <i>Leuk Lymphoma</i>. 2011;52(12):2237-2253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-drug-information/abstract-text/21827361/pubmed\" target=\"_blank\" id=\"21827361\">21827361</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. <i>Blood</i>. 2004;104(6):1624-1630.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-drug-information/abstract-text/15178574/pubmed\" target=\"_blank\" id=\"15178574\">15178574</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9745 Version 119.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206778\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50616077\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F206800\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F206781\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F206794\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F206782\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7697743\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22125178\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F44305358\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206757\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F206742\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F206760\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F206758\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F206808\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206749\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206763\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206746\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299829\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222178\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206753\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F206766\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2238576\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F206755\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206745\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F206762\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323630\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038720\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9745|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pegaspargase-patient-drug-information\" class=\"drug drug_patient\">Pegaspargase: Patient drug information</a></li><li><a href=\"topic.htm?path=pegaspargase-pediatric-drug-information\" class=\"drug drug_pediatric\">Pegaspargase: Pediatric drug information</a></li></ul></div></div>","javascript":null}